WO2005082395A1 - 新規な育毛剤、抗脱毛症剤 - Google Patents
新規な育毛剤、抗脱毛症剤 Download PDFInfo
- Publication number
- WO2005082395A1 WO2005082395A1 PCT/JP2005/004033 JP2005004033W WO2005082395A1 WO 2005082395 A1 WO2005082395 A1 WO 2005082395A1 JP 2005004033 W JP2005004033 W JP 2005004033W WO 2005082395 A1 WO2005082395 A1 WO 2005082395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- hair
- pro
- hair growth
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention provides a brightening agent for a hair restorer containing an peptide represented by Arg-Pro-Leu-Lys-Pro-Trp as an active ingredient. Furthermore, the present invention relates to a method for promoting hair growth using the above-mentioned peptide. Further, the present invention relates to an anti-alopecia agent comprising a peptide represented by ro-Leu-Lys_field and Arg-PPro-Trp as an active ingredient. Furthermore, the present invention relates to a method for suppressing hair loss using the above peptide.
- Hair loss is not a life-threatening problem, but its psychological effect is very large, and it is said that about 23 million people in Japan suffer from hair loss or hair loss. Among them, about 1Z4 are using hair restorer, and many people are not satisfied with the effect of hair restorer currently on the market.
- the search for new hair growth-promoting substances based on the results of basic research on the mechanism of hair growth and hair loss and the elucidation of their mechanisms are currently one of the important research issues, and the quality of life of people suffering from the hair loss problem ( It is expected to contribute to improvement of QOL).
- RP LKPW obtained by partially substituting the amino acid residue of OV okinin (2-7) (RADHPF), which is an arterial relaxing peptide derived from ovalbumin, is used in spontaneously hypertensive rats (SHR). Oral administration of the compound showed a significant blood pressure effect, and found that the effect was mediated by angiotensin type 2 receptor (AT2-R).
- a patent application has been filed for the RPLKPW peptide itself as a novel peptide having a blood pressure lowering effect (JP-A-2002-080496).
- minoxidil obtained as arterial relaxation and antihypertensive agent has hair growth promoting effect It is known that its action involves the sulfonylurea receptor (SUR). Although minoxidil and RPLKPW act at different receptors, they have in common that they have vasorelaxant and hypotensive effects. However, the effect of RPLKPW on promoting hair growth has not been studied so far.
- SUR sulfonylurea receptor
- a food for the purpose of hair growth there is known a food containing an extract of Amachiadul, a swordfish and a kelp extract.
- an oral depilatory agent comprising an oolong tea extract as an active ingredient, which can suppress, improve or prevent alopecia as a side effect of an anticancer agent (JP-A-9-309840).
- Finasteride a Type II 5 ⁇ reductase inhibitor, is also known as an oral hair restorer (J. of American Academy of Dermatology (1998) 39, PP 578-589).
- this drug is a drug that acts on the metabolism of male sex hormones, and there are concerns about its side effects, and there are many precautions and restrictions on its use.
- an object of the present invention is to examine the hair growth-promoting action and anti-hair loss action of RPLKPW, and to contribute the findings to the development of new hair growth agents and anti-alopecia agents. Given the large number of people suffering from hair loss and hair loss, providing new hair growth agents is considered to be significant.
- the present inventors have found that a significant hair growth promoting effect can be obtained when the peptide is mixed with a feed and orally ingested by mice for the purpose of examining the hair growth promoting effect of RP LKPW. It is considered that the hair growth promoting effect of the peptide is due to the promotion of the transition of the hair cycle from the telogen to the anagen. Accordingly, the present invention provides a hair restorer containing a peptide represented by Arg-Pro-Leu-Lys_Pro-Trp as an active ingredient, and a method for promoting hair growth using the above-mentioned peptide. Things.
- the present invention provides an anti-alopecia agent comprising a peptide represented by Arg-Pro_Leu-Lys-Pro-Trp as an active ingredient, and a method for suppressing hair loss using the peptide. Is provided.
- a hair restorer containing a peptide represented by Arg-Pro-Leu-Lys-Pro-Trp as an active ingredient, and a method of promoting hair growth using the above-mentioned peptide are disclosed. sponsored. Further, the present invention provides an anti-alopecia agent comprising a peptide represented by Arg-Pro-Leu-Lys-Pro-Trp as an active ingredient, and a method for suppressing hair loss using the peptide.
- the hair growth-promoting action and the anti-hair loss action of the peptide of the present invention are effective by oral administration, so that they can be easily taken, and it is considered likely that many people will be alert.
- the peptide is effective as a hair restorer, it is possible to develop, for example, a hair restorer, a hair restorer, and a hair restorer by using the knowledge of the present invention. Hair loss is often seen as a side effect of anticancer drugs, and it is not a life-threatening problem for patients receiving anticancer drugs. However, considering mental distress, the anti-alopecia agent of the present invention is significant.
- FIG. 1 is a photograph in which the hair growth promoting effect on the back of the mouse was evaluated in the control group and the RP LKPW administration group.
- FIG. 2 is a graph comparing the ratio of the hairy portion between the control group and the RPLKPW-administered group.
- FIG. 3 is a graph showing the proportion of hair follicles in the Age age VI stage in all hair follicles in the control group and the RPLKPW-administered group.
- FIG. 4 is a graph showing the change over time of the effect of RPLKPW on the expression level of VEGF mRNA in human dermal papilla cells.
- FIG. 5 is a graph showing the effect of suppressing hair loss by etoposide by RPLKPW.
- This effort is a hair restorer containing the peptide represented by Arg-Pro-Leu-Lys-Pro-Trp as an active ingredient.
- the present invention is an anti-alopecia agent comprising, as an active ingredient, a peptide represented by Arg-Pro-Leu-LysPro-Trp. Since the above-mentioned peptide has a hair growth-promoting action, it is possible to prepare a hair-growth agent containing the peptide as an active ingredient. Further, a method of promoting hair growth using the above-mentioned peptide is also within the scope of the present invention.
- the above-mentioned peptide can be used to particularly suppress hair loss as a side effect of an anticancer drug.
- Arg mentioned above indicates arginine
- Pro indicates proline
- Leu indicates leucine
- Lys indicates lysine
- Trp indicates tryptophan. All such amino acids are in the L-form.
- the peptide of the present invention can be obtained by a peptide synthesis method. That is, in a liquid-phase method or a solid-phase method, which is a method usually used for peptide synthesis, a raw material having a reactive carboxyl group corresponding to one of two types of fragments bisected at any position of a peptide bond.
- a raw material having a reactive amino group corresponding to the other fragment and an active ester such as ⁇ 3 ⁇ 4 :, 2- (lH-Benzotriazole-1-yl) -1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) Can be condensed using a method using carbodiimide or a method using carbodiimide. When the resulting condensate has a protecting group, it can also be produced by removing the protecting group.
- protecting groups that should not take part in the reaction in this reaction step are protected by protecting groups.
- protecting group for the amino group include benzyloxycarbonyl (Bz), t-butyloxycarbonyl (Boc), p-biphenylisopropylproproxycarbonyl, carbonyl, and 9-fluorenylmethyloxycarbonyl. (Fmo c).
- carboxyl group-protecting agent include groups capable of forming alkyl esters, benzyl esters, and the like. , P-alkoxy benzyl alcohol bound to a carrier such as a resin. Condensation reaction Or in the presence of a condensing agent such as N-protected amino acid active ester or peptide active ester.
- the protecting group is removed, but in the case of the solid phase method, the bond between the C-terminal of the peptide and the resin is further cleaved.
- the peptide of the present invention is purified according to a usual method. For example, ion exchange chromatography, reverse phase liquid chromatography, affinity chromatography and the like can be mentioned.
- the synthesized peptide is analyzed by a protein sequencer, GC-MS, etc., which reads the amino acid sequence from the C-terminal by the Edman degradation method.
- the hair growth peptide and the anti-alopecia peptide of the present invention have the advantage of being effective by oral administration, but are not limited thereto, and the administration route may be any of oral administration, parenteral administration, and rectal administration. Can also be adopted.
- the hair restorer and anti-alopecia of the present invention can be administered orally or parenterally.
- the dosage of this peptide varies depending on the type of compound, the administration method, the condition and age of the recipient, etc., but is usually 0.01 mg kg to 100 mg Zkg per day, preferably 0.1 mg mg to kg. :! OmgZkg.
- the peptide of the present invention is usually administered in the form of a preparation prepared by mixing with a preparation carrier.
- a carrier for pharmaceutical preparations a resin substance that is commonly used in the field of pharmaceutical preparations and that does not react with the peptide of the present invention is used.
- examples of such substances include lactose, glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium metasilicate aluminate, synthetic aluminum silicate, sodium carboxymethylcellulose, hydroxypropyl starch, Carboxymethylcellulose calcium, ion exchange resin, methinoresenorelose, gelatin, gum arabic, hydroxypropinoresenorelose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, light silicic anhydride, magnesium stearate , Talc, tragacanth, bentonite, veegum, oxidized titanium, sorbitan fatty acid ester, lauryl sulfate Sodium acid, glycerin, fatty acid glycerin ester, purified lanolin, glycerated gelatin, polysorbate, macrogol, vegetable oil, wax, liquid paraffin, white petrolatum, fluorocarbon, non-ionic acid,
- Dosage forms include tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, and the like. These preparations are prepared according to a conventional method. In the case of a liquid preparation, it may be in the form of being dissolved or suspended in water or another appropriate solvent at the time of use. Tablets and granules may be coated by a known method.
- the peptide is prepared by dissolving the peptide of the present invention in water.If necessary, the peptide may be dissolved in a physiological saline solution or a glucose solution, or a buffer or a preservative may be added. Is also good.
- These preparations may contain the peptide of the present invention in a proportion of 0.01% to 100% by weight, preferably 1 to 90% by weight. These formulations may also contain other therapeutically valuable ingredients.
- the active ingredient and excipient components such as lactose, starch, crystalline cellulose, calcium lactate, and caffeic anhydride can be mixed together to form a powder, and if necessary, sucrose.
- a binder such as hydroxypropylcellulose and polypyrrolopyridone, and a disintegrant such as carboxymethylcellulose and carboxymethylcellulose are added and granulated by wet or dry granulation.
- these powders and granules may be compressed as they are or by adding a lubricant such as magnesium stearate or talc.
- These granules or tablets are coated with an enteric base such as hydroxypropylmethylcellulose phthalate, methyl methacrylate-methyl methacrylate polymer, etc., and coated with an enteric solvent preparation, or with ethyl cellulose, carnauba wax, dandelion oil, etc. It can be a sustained-release preparation.
- an enteric base such as hydroxypropylmethylcellulose phthalate, methyl methacrylate-methyl methacrylate polymer, etc.
- an enteric solvent preparation or with ethyl cellulose, carnauba wax, dandelion oil, etc. It can be a sustained-release preparation.
- the active ingredient is used as is, or glycerin, polyethylene glycol, sesame oil, ozzy After dissolving in oil, the capsules can be coated with a gelatin film to form soft capsules.
- a liquid preparation for oral administration the active ingredient and a sweetener such as sucrose, sorbitol, and glycerin are dissolved in water to give a clear syrup, and then an elixir by adding essential oils and ethanol.
- a sweetener such as sucrose, sorbitol, and glycerin
- glycerin a sweetener
- a sweetener such as sucrose, sorbitol, and
- the active ingredient may be adjusted, if necessary, to a pH adjuster such as hydrochloric acid, sodium hydroxide, lactose, lactic acid, sodium, sodium monohydrogen phosphate, sodium dihydrogen phosphate, or the like.
- a pH adjuster such as hydrochloric acid, sodium hydroxide, lactose, lactic acid, sodium, sodium monohydrogen phosphate, sodium dihydrogen phosphate, or the like.
- an isotonic agent such as dani sodium, glucose, etc.
- mannitol, dextrin, cyclodextrin, gelatin, etc. and freeze-dry under vacuum. May be used as an injection.
- reticin, polysorbate 80, polyoxyethylene castor oil and the like can be added to the active ingredient and emulsified in water to prepare an emulsion for injection.
- the active ingredient is moistened together with a suppository base such as cocoa butter, fatty acid tri-, di- and monoglycerides, polyethylene glycol, etc., dissolved and poured into molds, or cooled or cooled.
- a suppository base such as cocoa butter, fatty acid tri-, di- and monoglycerides, polyethylene glycol, etc.
- the components may be dissolved in polyethylene glycol, soybean oil, etc., and then coated with a gelatin film.
- the active ingredient is added to white petrolatum, beeswax, liquid paraffin, polyethylene glycol, etc. and, if necessary, humidified and kneaded to form an ointment, rosin, alkyl acrylate After kneading with adhesive such as coalescing, it is spread on non-woven fabric such as polyalkyl to form tape.
- the hair growth peptide of the present invention can be administered in various foods and drinks or in the form of so-called subliment.
- the hair-growing peptide of the present invention can be incorporated into commonly eaten and eaten foods and seasonings, and such foods and drinks can be produced by ordinary methods. It is not particularly limited.
- the hair-growing peptide of the present invention can be blended into cosmetics in various forms such as hair cream, hair liquid or gel to prepare hair-growing cosmetics.
- various additives that are generally used can be blended into a cream-like, emulsion-like, or gel-like hair growth cosmetic.
- Such additives are not particularly limited, but may be mixed with a solvent such as water, a lower aliphatic alcohol such as ethanol, propanol or isopropanol, or a solvent such as glycerin and glycol such as 1,2-propylene glycol. Is possible.
- cation- and amphoteric fatty acids such as alkyltrimethionoleammonium salts, alkyl betaines, oxethylated fatty alcohols, fatty acid alkanolamides, and oxisedylated fatty acid esters are nonionic.
- Wetting agents or emulsifiers consisting of water-soluble surfactants, balm oils, opacifiers such as ethylene glycol distearate, fungicides or protective agents such as 2,4,4 trichloro-2-hydroxydiphenyl ether or methylisothiazolidone. Molds, buffers, humectants and anti-irritants can be used as appropriate.
- the present invention will be described in more detail, but does not limit the scope of the present invention. '
- the hair follicle is an organ that constantly grows in a certain cycle, and the hair cycle consists of anagen (An age), catagen (Catagen), and telogen (Te1ogen).
- anagen An age
- catagen Catagen
- Te1ogen telogen
- C 3 HZHe mice it is known that the hair cycle is synchronized with the Te 1 o g en phase for 50 days from the age of 7 weeks.
- the back of a 7-week-old male C3HZHe mouse whose hair cycle is in the T e1ogen phase is depilated with palycan and a shaver, and after a 3-day recovery period, lmg / mg from the age of 8 weeks. kg of RPLKPW was mixed with the powdered feed and fed freely.
- FIG. 1 shows a photograph of the back of the mouse.
- the upper part is a photograph of mice in the control group, and the lower part is a photograph of mice in the group to which RpLKPW was administered.
- Fig. 2 shows the results of image analysis and quantification of the photograph of Fig. 1.
- the vertical axis indicates the proportion of the hair-growing portion of the entire back of the mouse.
- hair follicles have a certain cycle, but the An agen stage can be further divided into six periods from stage I to stage VI. Transition from stage I to stage IV.
- the skin collected from the back of the mouse was stained with hematoxylin and eosin, and the observed skin tissue was observed.
- hair follicles translocating to Anagen were confirmed.
- hair follicles in the stage of AnageniiI were confirmed, old hair follicles remained, and new hair follicles extended only to the vicinity of the bulge.
- an increase in the number of hair follicles that had transitioned to the Ang en V I phase was confirmed, and a new hair follicle penetrated the epidermis. From these results, it is considered that hair growth is promoted in the RP LKPW administration group compared to the control group.
- FIG. 3 shows the results of quantitative determination of the proportion of the hair follicles in the Angen VI phase among all the hair follicles.
- the results in Figure 3 indicate that RP LKPW promotes the transition from the Te 1 o gen phase to the Ana gen phase. Therefore, it was found that the hair growth effect of RPLKP W is caused by such a shift in the hair cycle.
- Hair papilla cells which exist at the base of the hair follicle as stromal cells, release various cytokines and cell growth factors to the hair follicle epithelial cell stem cells, and perform hair follicle self-renewal .
- Minoxidil known as a hair restorer, is also known to promote the production of vascular endothelial cell growth factor (VEGF) from hair papillary cells. Therefore, the effect of VEGF on human head hair papilla cells was examined. Based on this study, RPLKPW Can further elucidate the mechanism of the hair growth promoting effect.
- VEGF vascular endothelial cell growth factor
- Human hair papilla cells were seeded at 5 ⁇ 10 4 cells in a 6-Omm dish and cultured for 23 hours. Thereafter, the medium was replaced, and the sample was added 1 hour later. After addition of the sample, the cells were cultured for 3, 6, 12 and 24 hours, then all RNA was extracted from the cells, and the amount of VEGF mRNA expression was determined by quantitative RT-PCR using AB IP ri sm7000. Was analyzed.
- Fig. 4 shows the results.
- the vertical axis represents the VEGF mRNA expression level in the RPLKPW administration group when the control VEGF mRNA expression level is 1, and the horizontal axis represents the stimulation time.
- anti-hair loss activity was evaluated in the following five groups (1) to (5). Each group of rats had one mother and was allowed free feeding. The mothers were allowed free inoculation of CLEA solid food CE 2 and had free access to drinking water. The drug was administered once a day between 10 am and 11 am. The peptide was administered orally once a day according to the protocol of 6 consecutive days from birth to 13 days after birth. Etoposide was administered at a dose of 1.2 mg / kg body weight intraperitoneally for three consecutive days from day 11 to day 13 of birth.
- Fig. 5 shows the results as a graph. In Fig. 5, * indicates a significant difference at the 1% risk rate, and *** indicates a significant difference at the 0.1% risk rate.
- a hair restorer containing a peptide represented by Arg-Pro-Leu-Lys_Pro-Trp as an active ingredient.
- an anti-alopecia agent comprising a peptide represented by Arg-Pro-Leu-Lys-Pro-Trp as an active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510557A JPWO2005082395A1 (ja) | 2004-03-02 | 2005-03-02 | 新規な育毛剤、抗脱毛症剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004057748 | 2004-03-02 | ||
JP2004-057748 | 2004-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005082395A1 true WO2005082395A1 (ja) | 2005-09-09 |
Family
ID=34909058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004033 WO2005082395A1 (ja) | 2004-03-02 | 2005-03-02 | 新規な育毛剤、抗脱毛症剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005082395A1 (ja) |
WO (1) | WO2005082395A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008530181A (ja) * | 2005-02-18 | 2008-08-07 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) | 少なくとも1種類の天然Ac−N−Ser−Asp−Lys−Proテトラペプチドまたはその類似体の1つの、毛髪喪失を遅延させ、かつ/または毛髪成長を刺激するための薬剤としての化粧料的使用 |
WO2012042010A1 (de) | 2010-10-01 | 2012-04-05 | Elfetin Cosmetics Ag | Pentapeptidderivate zur förderung des haarwachstums |
WO2014078929A1 (pt) * | 2012-11-26 | 2014-05-30 | Universidade Federal De Minas Gerais - Ufmg | Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos |
WO2017142305A1 (ko) * | 2016-02-18 | 2017-08-24 | (주)케어젠 | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
JP2019507187A (ja) * | 2016-02-18 | 2019-03-14 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛及び/又は育毛促進活性を示すペプチド及びその用途 |
JP2019508490A (ja) * | 2016-03-09 | 2019-03-28 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛促進活性及び/又はメラニン生成促進活性を示すペプチド及びその用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000143695A (ja) * | 1998-11-13 | 2000-05-26 | Univ Kyoto | 新規ペプチド、血圧降下剤および生理活性物質 |
JP2002080496A (ja) * | 2000-09-04 | 2002-03-19 | Univ Kyoto | 新規な降圧ペプチド |
JP2002284647A (ja) * | 2001-03-26 | 2002-10-03 | Cosmo Products Kk | 育毛・養毛剤 |
-
2005
- 2005-03-02 WO PCT/JP2005/004033 patent/WO2005082395A1/ja active Application Filing
- 2005-03-02 JP JP2006510557A patent/JPWO2005082395A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000143695A (ja) * | 1998-11-13 | 2000-05-26 | Univ Kyoto | 新規ペプチド、血圧降下剤および生理活性物質 |
JP2002080496A (ja) * | 2000-09-04 | 2002-03-19 | Univ Kyoto | 新規な降圧ペプチド |
JP2002284647A (ja) * | 2001-03-26 | 2002-10-03 | Cosmo Products Kk | 育毛・養毛剤 |
Non-Patent Citations (2)
Title |
---|
BRITISH JOURNAL OF DERMATOLOGY., vol. 147, no. 2, 2002, pages 276 - 280, XP002989829 * |
DATABASE EMBASE [online] TAKEDA H. ET AL: "Immunohistochemical study of angiotensin receptors in human anagen hair follicles and basal cell carcinoma.", XP002989828, Database accession no. (2002340784) * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008530181A (ja) * | 2005-02-18 | 2008-08-07 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) | 少なくとも1種類の天然Ac−N−Ser−Asp−Lys−Proテトラペプチドまたはその類似体の1つの、毛髪喪失を遅延させ、かつ/または毛髪成長を刺激するための薬剤としての化粧料的使用 |
WO2012042010A1 (de) | 2010-10-01 | 2012-04-05 | Elfetin Cosmetics Ag | Pentapeptidderivate zur förderung des haarwachstums |
WO2014078929A1 (pt) * | 2012-11-26 | 2014-05-30 | Universidade Federal De Minas Gerais - Ufmg | Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos |
EP3418293A4 (en) * | 2016-02-18 | 2019-03-20 | Caregen Co., Ltd. | PEPTIDE HAVING ACTIVITY PROMOTING HAIR GROWTH AND / OR ACTIVITY PROMOTING MELANIN PRODUCTION, AND USE THEREOF |
CN108633279A (zh) * | 2016-02-18 | 2018-10-09 | 凯尔格恩有限公司 | 呈现生发和/或育发促进活性的肽及其的用途 |
JP2019507187A (ja) * | 2016-02-18 | 2019-03-14 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛及び/又は育毛促進活性を示すペプチド及びその用途 |
WO2017142305A1 (ko) * | 2016-02-18 | 2017-08-24 | (주)케어젠 | 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
JP2019508489A (ja) * | 2016-02-18 | 2019-03-28 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛促進活性及び/又はメラニン生成促進活性を示すペプチド及びその用途 |
US10508140B2 (en) | 2016-02-18 | 2019-12-17 | Caregen Co., Ltd. | Peptide having hair growth-promoting activity and/or melanin generation-promoting activity, and use thereof |
JP2020105197A (ja) * | 2016-02-18 | 2020-07-09 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛及び/又は育毛促進活性を示すペプチド及びその用途 |
JP2020105196A (ja) * | 2016-02-18 | 2020-07-09 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛及び/又は育毛促進活性を示すペプチド及びその用途 |
CN108633279B (zh) * | 2016-02-18 | 2021-11-05 | 凯尔格恩有限公司 | 呈现生发和/或育发促进活性的肽及其的用途 |
JP2019508490A (ja) * | 2016-03-09 | 2019-03-28 | ケアジェン カンパニー, リミテッドCaregen Co., Ltd. | 発毛促進活性及び/又はメラニン生成促進活性を示すペプチド及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005082395A1 (ja) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3759748B2 (ja) | 成長ホルモン放出性を有する化合物 | |
JPH09507217A (ja) | 成長ホルモン放出特性を持つ化合物 | |
WO2005082395A1 (ja) | 新規な育毛剤、抗脱毛症剤 | |
JP2002527354A5 (ja) | ||
JP2021080273A (ja) | ミノキシジルとペプチドの結合体 | |
JP5048372B2 (ja) | 育毛促進剤 | |
JP4461261B2 (ja) | 新規な育毛剤 | |
JP2002508331A (ja) | ファゴサイトーシスおよびicam−1発現を調節するための組成物および方法 | |
JP3093378B2 (ja) | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 | |
JP3073762B2 (ja) | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 | |
JP3716298B2 (ja) | 新規な降圧ペプチド | |
JP2007182414A (ja) | 新規なかつお節ペプチド、l−バリル−l−プロリン及び血圧降下剤 | |
JP2005082489A (ja) | 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド | |
JP2005082489A6 (ja) | 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド | |
JP3031693B2 (ja) | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 | |
JP4263892B2 (ja) | アンジオテンシン変換酵素阻害剤含有組成物の製造方法 | |
JP3728494B2 (ja) | 新規な血清コレステロール低下ペプチド | |
JP2003277279A (ja) | エンドセリン拮抗剤 | |
JP3992143B2 (ja) | 新規生理活性ペプチド | |
JP4242728B2 (ja) | 新規生理活性ペプチド及びその用途 | |
JP3660978B2 (ja) | 抗健忘症ペプチド | |
JP3723838B2 (ja) | 新規な抗脱毛ペプチド | |
JP2953634B2 (ja) | 新規ペプチド、その製造法及び用途 | |
JP3709425B2 (ja) | 新規なトリペプチドおよびアンジオテンシン変換酵素阻害剤 | |
JP3629038B2 (ja) | アンギオテンシン変換酵素阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510557 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |